Journal
RETROVIROLOGY
Volume 10, Issue -, Pages -Publisher
BMC
DOI: 10.1186/1742-4690-10-72
Keywords
-
Categories
Funding
- Bill and Melinda Gates Foundation
- International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Consortium
- Dormeur Investment Services Ltd.
- EP Abraham Research Fund
- MRC [G0502048, G0000635] Funding Source: UKRI
- Medical Research Council [G0000635, G0502048] Funding Source: researchfish
Ask authors/readers for more resources
The focus of most current HIV-1 vaccine development is on antibody-based approaches. This is because certain antibody responses correlated with protection from HIV-1 acquisition in the RV144 phase III trial, and because a series of potent and broad spectrum neutralizing antibodies have been isolated from infected individuals. Taken together, these two findings suggest ways forward to develop a neutralizing antibody-based vaccine. However, understanding of the correlates of protection from disease in HIV-1 and other infections strongly suggests that we should not ignore CTL-based research. Here we review recent progress in the field and highlight the challenges implicit in HIV-1 vaccine design and some potential solutions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available